[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 1 Subunit Alpha (Sodium Channel Protein Brain I Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.1 or SCN1A) Drugs in Development by Therapy Areas and Indic...

May 2022 56 pages

Sodium Channel Protein Type 10 Subunit Alpha (Peripheral Nerve Sodium Channel 3 or Voltage Gated Sodium Channel Subunit Alpha Nav1.8 or SCN10A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 10 Subunit Alpha (Peripheral Nerve Sodium Channel 3 or Voltage Gated Sodium Channel Subunit Alpha Nav1.8 or SCN10A) Drugs in Development by Therapy Areas and Indications, S...

May 2022 62 pages

Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.9 or SCN11A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.9 or SCN11A) Drugs in...

May 2022 36 pages

Sodium Channel Protein Type 2 Subunit Alpha (HBSC II or Sodium Channel Protein Brain II Subunit Alpha or Sodium Channel Protein Type II Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.2 or SCN2A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 2 Subunit Alpha (HBSC II or Sodium Channel Protein Brain II Subunit Alpha or Sodium Channel Protein Type II Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1...

May 2022 51 pages

Sodium Channel Protein Type 3 Subunit Alpha (Voltage Gated Sodium Channel Subtype III or Voltage Gated Sodium Channel Subunit Alpha Nav1.3 or SCN3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 3 Subunit Alpha (Voltage Gated Sodium Channel Subtype III or Voltage Gated Sodium Channel Subunit Alpha Nav1.3 or SCN3A) Drugs in Development by Therapy Areas and Indicatio...

May 2022 47 pages

Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) Drugs in Development by Therapy Areas a...

May 2022 45 pages

Sodium Channel Protein Type 5 Subunit Alpha (Sodium Channel Protein Cardiac Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.5 or SCN5A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 5 Subunit Alpha (Sodium Channel Protein Cardiac Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.5 or SCN5A) Drugs in Development by Therapy Areas an...

May 2022 49 pages

Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A) Drugs in Development by Therapy...

May 2022 100 pages

Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mo...

May 2022 125 pages

Solute Carrier Family 12 Member 2 (Basolateral Na-K-Cl Symporter or Bumetanide Sensitive Sodium (Potassium) Chloride Cotransporter 1 or SLC12A2 or NKCC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 12 Member 2 (Basolateral Na-K-Cl Symporter or Bumetanide Sensitive Sodium (Potassium) Chloride Cotransporter 1 or SLC12A2 or NKCC1) Drugs in Development by Therapy Areas and Indi...

May 2022 35 pages

Solute Carrier Family 12 Member 3 (Na-Cl Cotransporter or NCC or Na-Cl Symporter or Thiazide Sensitive Sodium Chloride Cotransporter or SLC12A3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 12 Member 3 (Na-Cl Cotransporter or NCC or Na-Cl Symporter or Thiazide Sensitive Sodium Chloride Cotransporter or SLC12A3) Drugs in Development by Therapy Areas and Indications,...

May 2022 43 pages

Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Drugs in Development by Therapy Areas and Indi...

May 2022 52 pages

Sphingosine 1-Phosphate Receptor 5 (Endothelial Differentiation G Protein Coupled Receptor 8 or Sphingosine 1 Phosphate Receptor Edg 8 or S1PR5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Sphingosine 1-Phosphate Receptor 5 (Endothelial Differentiation G Protein Coupled Receptor 8 or Sphingosine 1 Phosphate Receptor Edg 8 or S1PR5) Drugs in Development by Therapy Areas and Indications,...

May 2022 37 pages

Stimulator Of Interferon Genes Protein (Endoplasmic Reticulum Interferon Stimulator or Mediator Of IRF3 Activation or Transmembrane Protein 173 or STING or TMEM173) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Stimulator Of Interferon Genes Protein (Endoplasmic Reticulum Interferon Stimulator or Mediator Of IRF3 Activation or Transmembrane Protein 173 or STING or TMEM173) Drugs in Development by Therapy Are...

May 2022 101 pages

Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2) Drugs in Development by Therapy Areas and Indicati...

May 2022 36 pages

T Cell Immunoreceptor With Ig And ITIM Domains (V Set And Immunoglobulin Domain Containing Protein 9 or V Set And Transmembrane Domain Containing Protein 3 or TIGIT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

T Cell Immunoreceptor With Ig And ITIM Domains (V Set And Immunoglobulin Domain Containing Protein 9 or V Set And Transmembrane Domain Containing Protein 3 or TIGIT) Drugs in Development by Therapy Ar...

May 2022 77 pages

Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) Drugs in Development by...

May 2022 37 pages

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 76 pages

Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA) Drugs in Development by Therapy Areas and Indicat...

May 2022 39 pages

Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molec...

May 2022 59 pages

Transcriptional Enhancer Factor TEF-1 (NTEF-1 or Protein GT-IIC or TEA Domain Family Member 1 or Transcription Factor 13 or TEAD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transcriptional Enhancer Factor TEF-1 (NTEF-1 or Protein GT-IIC or TEA Domain Family Member 1 or Transcription Factor 13 or TEAD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 37 pages

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Drugs in Development by Therapy A...

May 2022 42 pages

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Drugs in Development by Therapy Areas and Ind...

May 2022 40 pages

Translocator Protein (Mitochondrial Benzodiazepine Receptor or PKBS or Peripheral Type Benzodiazepine Receptor or PBR or TSPO) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Translocator Protein (Mitochondrial Benzodiazepine Receptor or PKBS or Peripheral Type Benzodiazepine Receptor or PBR or TSPO) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 35 pages

Tripeptidyl Peptidase 1 (Tripeptidyl Aminopeptidase or Lysosomal Pepstatin Insensitive Protease or Cell Growth Inhibiting Gene 1 Protein or TPP1 or EC 3.4.14.9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tripeptidyl Peptidase 1 (Tripeptidyl Aminopeptidase or Lysosomal Pepstatin Insensitive Protease or Cell Growth Inhibiting Gene 1 Protein or TPP1 or EC 3.4.14.9) Drugs in Development by Therapy Areas a...

May 2022 35 pages

Tumor Necrosis Factor Ligand Superfamily Member 10 (Apo 2 Ligand or TNF Related Apoptosis Inducing Ligand or Protein TRAIL or CD253 or TNFSF10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 10 (Apo 2 Ligand or TNF Related Apoptosis Inducing Ligand or Protein TRAIL or CD253 or TNFSF10) Drugs in Development by Therapy Areas and Indications, S...

May 2022 36 pages

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoproteger...

May 2022 71 pages

Tumor Necrosis Factor Ligand Superfamily Member 13 (A Proliferation Inducing Ligand or APRIL or TNF And APOL Related Leukocyte Expressed Ligand 2 or TNF Related Death Ligand 1 or CD256 or TNFSF13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 13 (A Proliferation Inducing Ligand or APRIL or TNF And APOL Related Leukocyte Expressed Ligand 2 or TNF Related Death Ligand 1 or CD256 or TNFSF13) Dru...

May 2022 37 pages

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Drug...

May 2022 37 pages

Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) Drugs in Development by Therapy Areas and Indi...

May 2022 38 pages

Tumor Necrosis Factor Receptor Superfamily Member 1B (Tumor Necrosis Factor Receptor 2 or p75 or p80 TNF Alpha Receptor or CD120b or TNFRSF1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 1B (Tumor Necrosis Factor Receptor 2 or p75 or p80 TNF Alpha Receptor or CD120b or TNFRSF1B) Drugs in Development by Therapy Areas and Indications, St...

May 2022 53 pages

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) Drugs in Development by Therapy Are...

May 2022 70 pages

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indicati...

May 2022 124 pages

Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2) Drugs in Development by Ther...

May 2022 43 pages

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stag...

May 2022 112 pages

Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56...

May 2022 38 pages

Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or PTPN11 or EC 3.1.3.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or PTPN11 or EC 3.1.3.48) Drugs in Development by The...

May 2022 57 pages

Ubiquitin Carboxyl Terminal Hydrolase 14 (Deubiquitinating Enzyme 14 or Ubiquitin Thioesterase 14 or Ubiquitin Specific Processing Protease 14 or USP14 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 14 (Deubiquitinating Enzyme 14 or Ubiquitin Thioesterase 14 or Ubiquitin Specific Processing Protease 14 or USP14 or EC 3.4.19.12) Drugs in Development by Therapy...

May 2022 35 pages

Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub Specific Protease 30 or USP30 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub Specific Protease 30 or USP30 or EC 3.4.19.12) Drug...

May 2022 35 pages

Ubiquitin Carboxyl Terminal Hydrolase 7 (Deubiquitinating Enzyme 7 or Ubiquitin Thioesterase 7 or Herpesvirus Associated Ubiquitin Specific Protease or Ubiquitin Specific Processing Protease 7 or USP7 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 7 (Deubiquitinating Enzyme 7 or Ubiquitin Thioesterase 7 or Herpesvirus Associated Ubiquitin Specific Protease or Ubiquitin Specific Processing Protease 7 or USP7...

May 2022 38 pages

Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 35 pages

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 2.3.2.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or...

May 2022 45 pages

UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108) Drugs in Development by Therapy Areas and Indication...

May 2022 39 pages

V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation (Platelet Receptor Gi24 or Stress Induced Secreted Protein 1 or PD1H or V Set Domain Containing Immunoregulatory Receptor or B7H5 or VISTA or VSIR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation (Platelet Receptor Gi24 or Stress Induced Secreted Protein 1 or PD1H or V Set Domain Containing Immunoregulatory Receptor or B7H...

May 2022 42 pages

Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or F...

May 2022 77 pages

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Develo...

May 2022 138 pages

Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indicatio...

May 2022 71 pages

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) Drugs in Development by Ther...

May 2022 36 pages

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 38 pages

Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 45 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

Date

Pages

Offers